CDA | Evidence Driven
CDA | Evidence Driven

teprotumumab

Details

Files
Generic Name:
teprotumumab
Project Status:
Active
Therapeutic Area:
Thyroid Eye Disease (TED), acute
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0853-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Teprotumumab is indicated in adults for the treatment of moderate to severe Thyroid Eye Disease (TED).
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
​Teprotumumab is indicated in adults for the treatment of moderate to severe Thyroid Eye Disease (TED).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open12-Sep-24
Call for patient/clinician input closed04-Nov-24
Submission received25-Oct-24
Submission accepted08-Nov-24
Review initiated12-Nov-24
Draft CADTH review report(s) provided to sponsor for comment07-Feb-25
Deadline for sponsors comments19-Feb-25
CADTH review report(s) and responses to comments provided to sponsor13-Mar-25
Expert committee meeting (initial)26-Mar-25
Draft recommendation issued to sponsorApril 07, 2025
To
April 09, 2025
Draft recommendation posted for stakeholder feedback17-Apr-25
End of feedback period05-May-25

Files

Patient and Clinician Group Input View PDF
Last Updated : November 14, 2024